Drug
CPI-0610 clinical trials
Also written Pelabresib, CPI-0610 and DAK539.
- studies test it
- 11
- open now
- 5
- in phase 3
- 3
- first study started
- 2013
Keep track of what changes. Save the CPI-0610 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2024 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Novartis Pharmaceuticals (7) · Constellation Pharmaceuticals (3) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Ruxolitinib (1) · Repaglinide (1) · Midazolam (1) · Drospirenone (1) · Ethinyl Estradiol (1) · Phenytoin (1) · Itraconazole (1)
Studies
Open first, then newest update. How each study uses CPI-0610 is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)RecruitingPhase 3Novartis PharmaceuticalsNCT07357727Written as Pelabresib
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced MalignanciesRecruitingPhase 1Novartis PharmaceuticalsNCT07340190Written as pelabresib
- A Drug-drug Interaction Study to Assess the Effect of Phenytoin and Itraconazole on the Pharmacokinetics of Pelabresib in Healthy ParticipantsRecruitingPhase 1Novartis PharmaceuticalsNCT07783503Written as Pelabresib
- Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic ImpairmentRecruitingPhase 1Novartis PharmaceuticalsNCT07422610Written as pelabresib
- An Extension Study for Patients Previously Enrolled in Studies With PelabresibRecruitingPhase 3Novartis PharmaceuticalsNCT06401356Written as Pelabresib
- Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisActive, not recruitingPhase 1Novartis PharmaceuticalsNCT07340138Written as Pelabresib
- Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)Active, not recruitingPhase 3Novartis PharmaceuticalsNCT04603495Written as Pelabresib
- Study Evaluating Food Effect and QTc in Patients With Advanced MalignanciesCompletedPhase 1Constellation PharmaceuticalsNCT05391022Written as Pelabresib
- A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive LymphomaCompletedPhase 1Constellation PharmaceuticalsNCT01949883Written as CPI-0610
- A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple MyelomaCompletedPhase 1Constellation PharmaceuticalsNCT02157636Written as CPI-0610
- Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath TumorsWithdrawnPhase 2University of Texas Southwestern Medical CenterNCT02986919Written as CPI-0610